

LIST OF TABLES

		Page
Table I	Number of patients whose data were used for analysis in different chapters of Report No. 10	14
Table 1.1	Lifetime risk of breast cancer of Hong Kong women (averaged data from 2010 to 2015)	23
Table 1.2	Dietary habits, exercise habits and stress level at diagnosis (N=16,743)	26
Table 1.3	Body mass index at diagnosis (N=16,743)	27
Table 1.4	Family history of breast cancer at diagnosis (N=16,743)	27
Table 1.5	Personal histories of tumours of patient cohort at diagnosis (N=16,743)	27
Table 1.6	Origins of malignant tumours reported by patients (N=283)	28
Table 1.7	History of breast condition / disease at diagnosis	28
Table 1.8	Early menarche, late menopause and reproductive history at diagnosis	29
Table 1.9	Number of live births reported by patient cohort (N=12,735)	30
Table 1.10	Use of hormonal contraceptives at diagnosis (N=16,743)	30
Table 1.11	Use of hormone replacement therapy (in post-menopausal patients) at diagnosis (N=8,735)	30
Table 1.12	Ten most common risk factors for breast cancer in patient cohort (N=16,743)	31
Table 1.13	Breast screening habits by age group	32
Table 1.14	Breast screening habits by education level	33
Table 1.15	Breast screening habits by monthly household income (HK\$)	34
Table 1.16	Breast screening habits by district of residence	35
Table 2.1	Method of first breast cancer detection by type of medical service received at cancer diagnosis and treatment (N=15,673)	41
Table 2.2	Method of first breast cancer detection by type of cancer (N=15,663)	42
Table 2.3	Method of first breast cancer detection by cancer stage (N=15,146)	42
Table 2.4	Time interval between onset of symptoms and first medical consultation for patients who self-detected* their cancers (N=3,423)	43
Table 2.5	Time interval between onset of symptoms and first medical consultation for patients who self-detected* their cancers by type of medical service (N=3,423)	43
Table 2.6	Cancer stage at diagnosis among self-detected* patients by time interval between onset of symptoms and first medical consultation (N=3,000)	44
Table 2.7	Sensitivity and diagnostic results of breast imaging tests (N=16,595)	45
Table 2.8	Mammographic findings of patients diagnosed through mammography (N=11,788)	46
Table 2.9	Mammographic density of breasts of patients diagnosed through mammogram by age group (N=8.183)	46



		Page
Table 2.10	Sensitivity and diagnostic results of breast tissue biopsies (N=16,595)	47
Table 2.11	Method of clinical staging in 7,016 invasive breast cancer patients	48
Table 2.12	Use of PET scan as a form of staging method among patients by cancer stage (N=7,016)	48
Table 2.13	Histological type, grading, multifocality and multicentricity of invasive breast cancers (N=14,234)	51
Table 2.14	Biological characteristics of invasive breast cancers (N=14,234)	52
Table 2.15	Biological subtypes of invasive tumours by cancer stage (N=13,355)	53
Table 2.16	Histological type, grading, multifocality and multicentricity of in situ breast cancers (N=2,194)	54
Table 2.17	Biological characteristics of in situ breast cancers (N=2,194)	54
Table 2.18	Type of surgery (N=16,583)	56
Table 2.19	Coverage of regional lymph nodes by adjuvant locoregional radiotherapy (N=6,478)	60
Table 2.20	Use of chemotherapy by age group and cancer stage at diagnosis (N=13,242)	61
Table 2.21	Number of treatment modalities received by patients by cancer stage (N=15,654)	68
Table 2.22	Follow-up of 14,699 patients	69
Table 2.23	Locoregional recurrence by type of surgery and cancer stage	70
Table 2.24	Sites involved in locoregional recurrence (N=388)	70
Table 2.25	Organs involved in distant recurrence (N=494)	71
Table 2.26	Locoregional and distant recurrence among invasive breast cancer patients by cancer stage	71
Table 2.27	Characteristics of breast cancer-specific deaths (N=181)	72
Table 3.1	Five most common forms of discomfort after surgery (N=14,681)	75
Table 3.2	Five most common forms of discomfort after radiotherapy (N=8,769)	76
Table 3.3	Five most common forms of discomfort after chemotherapy (N=8,954)	77
Table 3.4	Five most common forms of discomfort after endocrine therapy (N=9,452)	77
Table 3.5	Five most common forms of discomfort after anti-HER2 targeted therapy (N=1,810)	78
Table 3.6	Psychosocial impact of breast cancer	79
Table 3.7	Psychosocial adjustments and coping strategies for survivorship	80



LIST OF FIGURES

		Page
Figure I	Distribution of year of diagnosis of HKBCR participants	10
Figure II	Sources of patient consent in HKBCR reports	14
Figure 1.1	Distribution of age at diagnosis (N=16,743)	23
Figure 1.2	Occupation of patient cohort (N=16,743)	23
Figure 1.3	Education level of patient cohort (N=16,743)	24
Figure 1.4	Monthly household income (HK\$) of patient cohort (N=9,487)	24
Figure 1.5	District of residence of patient cohort (N=16,743)	24
Figure 1.6	Bra size of patient cohort (N=16,743)	25
Figure 1.7	Bra cup size of patient cohort (N=16,743)	25
Figure 1.8	Distribution of risk factors among patients at diagnosis (N=16,743)	31
Figure 2.1	Method of first breast cancer detection in the patient cohort (N=15,673)	41
Figure 2.2	Major presenting symptoms of self-detected* breast cancers in patient cohort (N=13,055)	42
Figure 2.3	Laterality of 16,595 breast cancer cases	44
Figure 2.4	Locations of malignant tumour on breasts within patient cohort (N=16,595)	45
Figure 2.5	Mammographic density of breasts of patients diagnosed through mammogram (N=8,463)	46
Figure 2.6	Cancer stage at diagnosis (N=16,595)	49
Figure 2.7	Distribution of tumour size (cm) of invasive breast cancers (N=12,213)	49
Figure 2.8	Number of positive axillary lymph nodes among patients with invasive breast cancers (N=13,904)	50
Figure 2.9	Distribution of tumour size (cm) of in situ breast cancers (N=1,781)	50
Figure 2.10	Type of surgery by age group (N=15,597)	57
Figure 2.11	Type of surgery by tumour size (N=13,965)	57
Figure 2.12	Type of surgery by cancer stage at diagnosis (N=15,766)	57
Figure 2.13	Type of surgery by type of medical service (N=15,668)	57
Figure 2.14	Type of nodal surgery by clinical nodal status (N=15,172)	58
Figure 2.15	Type of nodal surgery for invasive cancer by cancer stage (N=13,376)	58
Figure 2.16	Distribution of tumour size in invasive cancer with negative or positive nodal status (N=12,147)	58
Figure 2.17	Number of positive nodes by type of nodal surgery (N=15,118)	59
Figure 2.18	Patients who underwent both breast-conserving surgery and locoregional radiotherapy	60



		Page
Figure 2.19	Patients who underwent both mastectomy and locoregional radiotherapy by cancer stage (N=9,871)	60
Figure 2.20	Chemotherapy treatment by cancer stage (N=13,732)	61
Figure 2.21	Type of chemotherapy regimens in neoadjuvant setting in patients by biological subtype (N=939)	62
Figure 2.22	Type of chemotherapy regimens in adjuvant setting in patients by biological subtype (N=7,172)	63
Figure 2.23	Type of chemotherapy regimens in adjuvant setting in patients by cancer stage (N=7,314)	64
Figure 2.24	Type of chemotherapy regimens in palliative setting in patients by biological subtype (N=289)	65
Figure 2.25	Endocrine therapy rates by cancer stage (N=15,829)	66
Figure 2.26	Forms of endocrine therapy by age group (N=10,095)	66
Figure 2.27	Anti-HER2 targeted therapy rate in HER2 positive patients by cancer stage (N=2,944)	67
Figure 2.28	Type of complementary and alternative therapies used in 6,378 patients	68
Figure 3.1	Level of physical discomfort after surgery (N=14,681)	75
Figure 3.2	Level of physical discomfort by type of surgery (N=14,646)	75
Figure 3.3	Level of physical discomfort after radiotherapy (N=8,769)	76
Figure 3.4	Level of physical discomfort after radiotherapy by irradiated regions (N=5,998)	76
Figure 3.5	Level of physical discomfort after chemotherapy (N=8,954)	76
Figure 3.6	Level of physical discomfort after endocrine therapy (N=9,452)	77
Figure 3.7	Level of physical discomfort after anti-HER2 targeted therapy (N=1,810)	77
Figure 3.8	Level of physical discomfort after complementary and alternative therapies (N=6,378)	78
Figure 3.9	Change in outlook on life by age group (N=14,114)	79
Figure 3.10	Change in self-image by age group (N=14,114)	80
Figure 3.11	Level of worry about recurrence by age group (N=14,150)	80